Chemistry data
- Class
- dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
- Molecular weight
- 4813.5 g/mol
- Sequence
- YAibEGTFTSDVSSYLEEQAAKEFIAWLVKGRG-OH (39 amino acids; Aib = aminoisobutyric acid at position 2; C-20 fatty diacid conjugated to lysine at position 20)
- Half-life
- approximately 5 days (subcutaneous)
- Routes
- subcutaneous
- Studied doses
- subcutaneous 2.5 mg, 5 mg, 10 mg, 15 mg once weekly
Stato Normativo
- Stati Uniti
- fda_approved
- Unione Europea
- ema_approved
- Regno Unito
- mhra_approved
Come funziona
- Dual agonism at GIP and GLP-1 receptors with imbalanced biased signaling favoring GIPR engagement, enhancing insulin secretion in a glucose-dependent manner
- Suppression of glucagon secretion via GLP-1 receptor activation on pancreatic alpha cells during hyperglycemia
- Slowing of gastric emptying contributing to postprandial glucose reduction and increased satiety
- Central appetite suppression via brainstem circuits, modulated by GIP receptor activation attenuating GLP-1-induced nausea
- GIPR-mediated weight-independent insulin sensitization and adipocyte nutrient metabolism modulation
Risultati della ricerca
- blood-sugar-control clinical
- fat-loss clinical
- metabolic-health clinical
- cardiovascular-health clinical
Contesto di dosaggio
-
- Vie di Somministrazione
- subcutaneous
- Intervallo
- 2.5 mg, 5 mg, 10 mg, 15 mg once weekly
FDA-approved dosing: 2.5 mg starting dose titrated to 5 mg, 10 mg, or 15 mg once weekly for type 2 diabetes (Mounjaro) and obesity (Zepbound)
🧮 Reconstitution Calculator
Determine exactly how much bacteriostatic water to add and how many units to draw for your target dose.
Effetti collaterali: contesto di ricerca
- nausea
- diarrhea
- decreased appetite
- vomiting
- constipation
- dyspepsia
- abdominal pain
- injection site reactions
Il riassunto completo della ricerca arriverà presto. Nel frattempo, consulta i dati scientifici e i riferimenti PubMed sopra.